News & Updates

Timing of liquid LT4 intake doesn’t impact bioavailability
Timing of liquid LT4 intake doesn’t impact bioavailability
01 Aug 2022 byElvira Manzano

Bioavailability studies presented at ENDO 2022 showed that patients with hypothyroidism can safely take the liquid formulations of levothyroxine (LT4) 15 or 30 minutes before meals, without having to worry about food effect on bioavailability.

Timing of liquid LT4 intake doesn’t impact bioavailability
01 Aug 2022
Thyroid hormone sensitivity tied to advanced liver fibrosis in NAFLD
Thyroid hormone sensitivity tied to advanced liver fibrosis in NAFLD
30 Jul 2022

In euthyroid patients with nonalcoholic fatty liver disease (NAFLD), higher values of thyroid hormone sensitivity markers, such as the thyroid-stimulating hormone (TSH) index (TSHI) and thyroid feedback quantile-based index (TFQI), appear to aggravate the risk of advanced fibrosis, a recent study has found.

Thyroid hormone sensitivity tied to advanced liver fibrosis in NAFLD
30 Jul 2022
Parathyroidectomy effective for primary hyperparathyroidism regardless of localization technique
Parathyroidectomy effective for primary hyperparathyroidism regardless of localization technique
29 Jul 2022

Parathyroidectomy yields excellent surgical outcomes in patients with primary hyperparathyroidism (PHPT), whether or not intraoperative localization technique (IOLT) or intraoperative parathyroid hormone (IOPTH) monitoring have been used, reports a recent study.

Parathyroidectomy effective for primary hyperparathyroidism regardless of localization technique
29 Jul 2022
Glucose-lowering medications protect against glaucoma, AMD
Glucose-lowering medications protect against glaucoma, AMD
29 Jul 2022

While diabetes is a risk factor for cataract, glucose-lowering medications appear to have a protective effect on the risks of open-angle glaucoma (OAG) and age-related macular degeneration (AMD), as shown in a study.

Glucose-lowering medications protect against glaucoma, AMD
29 Jul 2022
Neutrophils release more cytokines in DM, HFpEF patients
Neutrophils release more cytokines in DM, HFpEF patients
27 Jul 2022

In patients with type 2 diabetes mellitus (DM) or heart failure with preserved ejection fraction (HFpEF), neutrophils seem to secrete more cytokines, contributing to low-grade chronic inflammation, a recent study reports.

Neutrophils release more cytokines in DM, HFpEF patients
27 Jul 2022
Growth hormone reduces liver fat, fibro-inflammation in obese/overweight adults with NAFLD
Growth hormone reduces liver fat, fibro-inflammation in obese/overweight adults with NAFLD
27 Jul 2022 byAudrey Abella

In adults with overweight/obesity and nonalcoholic fatty liver disease (NAFLD), daily administration of growth hormone (GH) reduced hepatic steatosis and improved markers of hepatic inflammation and fibrosis, a study has shown.

Growth hormone reduces liver fat, fibro-inflammation in obese/overweight adults with NAFLD
27 Jul 2022
Abdominal aortic calcification linked to CAD, CI in T2DM
Abdominal aortic calcification linked to CAD, CI in T2DM
26 Jul 2022

In patients with type 2 diabetes mellitus (T2DM), abdominal aortic calcification might be an important indicator of coronary artery disease (CAD) and cerebral infarction (CI), a new study has found.

Abdominal aortic calcification linked to CAD, CI in T2DM
26 Jul 2022